Stock comparison
Eli Lilly
Anbio Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
NNNN
Anbio Biotechnology
Market cap
$1.43B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | NNNN | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 58C | LLY |
| Benjamin Graham | 86A | 87A | NNNN |
| Philip Fisher | 86A | 89A | NNNN |
| Peter Lynch | 74B | 95A | NNNN |
| Joel Greenblatt | 78C | 36D | LLY |
| Charlie Munger | 85A | 73C | LLY |
| Terry Smith | 77C | 72C | LLY |
Side-by-side metrics
| Metric | LLY | NNNN |
|---|---|---|
| Market cap | $1T | $1.43B |
| P/E (TTM) | 36.6x | 171.9x |
| EV/EBIT | 34.1x | 212.9x |
| ROIC (TTM) | 32.06% | 21.48% |
| Gross margin | 83.51% | 87.06% |
| Net margin | 34.98% | 73.75% |
| Revenue CAGR 5y | 23.17% | 18.21% |
| EPS CAGR 5y | 40.81% | 58.42% |
| Debt / Equity | 1.4x | - |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $1.43B+100%
- EV/EBIT34.1xvs 212.9x+84%
- P/E (TTM)36.6xvs 171.9x+79%
NNNN leads on
- Debt / Equity-vs 1.4x+100%
- Net margin73.75%vs 34.98%+53%
- EPS CAGR 5y58.42%vs 40.81%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.